The burden of rheumatoid arthritis and access to treatment: determinants of access

J Lundqvist, F Kastäng, Gisela Kobelt, B Jönsson

Research output: Contribution to journalArticlepeer-review

15 Citations (SciVal)


As pan of the study "The Burden of Rheumatoid Arthritis (RA) and Patient Access to Treatment", this paper reviews the impact on access to RA drugs of the approval processes, pricing and funding decisions and times to market (access) in different countries. In addition, an overview of health technology assessments (HTA) and the economic literature related to RA treatments is provided. The time from approval to market access ranged from immediate to over 500 days in the countries included in the study. A total of 55 HTA reports were identified, 40 of them in the period between 2002 and 2006; 29 were performed by European HTA agencies, 14 in Canada and 7 in the United States. A total of 239 economic evaluations related to RA were identified in a specialized health economic database (HEED).
Original languageEnglish
Pages (from-to)S87-S93
JournalEuropean Journal of Health Economics
Issue numberSuppl. 2
Publication statusPublished - 2008

Subject classification (UKÄ)

  • Health Care Service and Management, Health Policy and Services and Health Economy


  • rheumatoid arthritis
  • health technology assessment
  • treatment access


Dive into the research topics of 'The burden of rheumatoid arthritis and access to treatment: determinants of access'. Together they form a unique fingerprint.

Cite this